Disease Domain | Count |
---|---|
Infectious Diseases | 20 |
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 22 |
Top 5 Target | Count |
---|---|
CYP51 (Yeast)(Lanosterol 14-alpha demethylase) | 20 |
KRAS G13D x PDE6D | 2 |
Target |
Mechanism KRAS G13D modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CYP51 (Yeast) inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CYP51 (Yeast) inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date23 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2023 |
Sponsor / Collaborator |
Start Date06 Jul 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CYP51 inhibitors-4c(Instituto Politécnico Nacional) ( CYP51 (Yeast) ) | Mycoses More | Preclinical |
CYP51 inhibitors-6c(Instituto Politécnico Nacional) ( CYP51 (Yeast) ) | Mycoses More | Preclinical |
CYP51 inhibitors-6f(Instituto Politécnico Nacional) ( CYP51 (Yeast) ) | Mycoses More | Preclinical |
CYP51 inhibitors-6a(Instituto Politécnico Nacional) ( CYP51 (Yeast) ) | Mycoses More | Preclinical |
CYP51 inhibitors-4b(Instituto Politécnico Nacional) ( CYP51 (Yeast) ) | Mycoses More | Preclinical |